Healthcare Services company Thyrocare Technologies announced Q3FY25 results Revenue: Rs 165.9 crore, compared to Rs 134.7 crore during Q3FY24, change 23% YoY. EBITDA: Rs 41.6 crore, compared to Rs 31.6 crore during Q3FY24, change 32% YoY. Consolidated gross margin stood at 73%, and normalized EBITDA margin was 30% PAT: Rs 18.9 crore, compared to Rs 14.6 crore during Q3FY24 30% YoY Pathology and Radiology segments grew by 24% YoY and 13% YoY respectively Result PDF
Conference Call with Thyrocare Technologies Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services company Thyrocare Technologies announced Q2FY25 results Financial Highlights: Consolidated Revenue increased by 20% year-over-year (YoY) with Pathology and Radiology segments growing by 20% YoY and 21% YoY respectively. Revenue from partnerships surged by 33% YoY, and franchise revenue saw 14% YoY growth. Consolidated gross margin stood at 71%, and normalized EBITDA margin was 29%. Standalone reported EBITDA grew by 33% YoY, while PAT increased by 45% YoY. Consolidated reported EBITDA grew by 28% YoY, while PAT increased by 29% YoY Business Highlights: Opened 2 new labs in Madurai and Surat. 28 NABL accredited labs at present out of 32 labs including Tanzania. 96% of our sample load is processed in NABL labs. Completed the acquisition of Polo Labs on July 29, 2024. Signed the Business Transfer Agreement to acquire the clinical diagnostic business of Vimta Labs on August 30, 2024, and completed the acquisition on October 11, 2024. Result PDF